Screener
Adaptive Biotechnologies ADPT Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 69,115 | 70,228 |
| Deferred revenue, less current portion | 807 | 1,006 |
| Revenue interest liability, net, less current portion | 124,749 | 126,566 |
| Other long-term liabilities | 20 | 20 |
| Total liabilities | 281,702 | 287,735 |
| Commitments and contingencies (Note 9) | ||
| Shareholders’ equity |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's long-term debt?
- Adaptive Biotechnologies (ADPT) reported long-term debt of $124.75M in Q1 2026.
- How has Adaptive Biotechnologies's long-term debt changed year-over-year?
- Adaptive Biotechnologies's long-term debt decreased by 5.2% year-over-year, from $131.55M to $124.75M.
- What is the long-term trend for Adaptive Biotechnologies's long-term debt?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's long-term debt has grown at a 0.3% compound annual growth rate (CAGR), from $125.36M to $126.57M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Adaptive Biotechnologies's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude